Since KRAS mutations are detected in as much as 25% of NSCLCs, and no targeted therapies have been approved for this subset population, trametinib, a selective allosteric inhibitor of MEK1/MEK2 that has preclinical and clinical activity in KRAS-mutant NSCLC, was analyzed here. This evidence concerns the gene MAP2K1 and non-small cell lung carcinoma.